Stock CRVO CERVOMED INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings CervoMed Inc.

Equities

CRVO

US15713L1098

Market Closed - Nasdaq
Other stock markets
 01:30:00 04/06/2024 am IST 		5-day change 1st Jan Change
19.66 USD +3.80% Intraday chart for CervoMed Inc. +5.19% +157.67%
29/05 JonesTrading Starts CervoMed With Buy Rating, $70 Price Target MT
20/05 CervoMed Names William Elder CFO MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analyst opinion has improved significantly over the past four months.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
CERVOMED INC. Stock CervoMed Inc.
+157.67% 16Cr -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.55% 12TCr
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.66% 11TCr
B+
BIONTECH SE Stock BioNTech SE
-2.53% 2.48TCr
B+
ARGENX SE Stock argenx SE
+1.37% 2.25TCr
B
GENMAB A/S Stock Genmab A/S
-9.72% 1.83TCr
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.28% 1.63TCr
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.92% 1.53TCr
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.19% 1.41TCr
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.83% 1.17TCr
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CRVO Stock
  4. Ratings CervoMed Inc.